Ironwood Pharmaceuticals (IRWD) Liabilities and Shareholders Equity (2016 - 2025)
Ironwood Pharmaceuticals' Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $396.9 million for Q4 2025.
- For Q4 2025, Liabilities and Shareholders Equity rose 13.11% year-over-year to $396.9 million; the TTM value through Dec 2025 reached $1.5 billion, down 7.1%, while the annual FY2025 figure was $396.9 million, 13.11% up from the prior year.
- Liabilities and Shareholders Equity for Q4 2025 was $396.9 million at Ironwood Pharmaceuticals, roughly flat from $396.1 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $1.2 billion in Q1 2023 and bottomed at $327.2 million in Q1 2025.
- The 5-year median for Liabilities and Shareholders Equity is $561.7 million (2021), against an average of $690.2 million.
- The largest annual shift saw Liabilities and Shareholders Equity surged 127.09% in 2021 before it crashed 62.02% in 2024.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.1 billion in 2021, then fell by 2.34% to $1.1 billion in 2022, then plummeted by 57.2% to $471.1 million in 2023, then fell by 25.51% to $350.9 million in 2024, then increased by 13.11% to $396.9 million in 2025.
- Per Business Quant, the three most recent readings for IRWD's Liabilities and Shareholders Equity are $396.9 million (Q4 2025), $396.1 million (Q3 2025), and $342.9 million (Q2 2025).